Hypertension Therapeutic Pipeline Outlook | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Companies Involved

August 25 14:20 2022
Hypertension Therapeutic Pipeline Outlook | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Companies Involved
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, nearly 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Hypertension therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development expected to launch in the coming years.

Hypertension Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypertension Market. 

The Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

DelveInsight’s Report covers around 100+ products under different phases of clinical development like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

 Hypertension Pipeline Analysis

Hypertension Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Hypertension with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Hypertension Treatment.

  • Hypertension key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hypertension market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/hypertension-pipeline-insight

Hypertension Therapeutics Landscape

There are approx. 100+ key companies which are developing therapies for Hypertension. Currently, Reata Pharmaceuticals has Hypertension drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Hypertension Therapeutics Market include:

Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision, Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics, Inc., Aadi Bioscience, Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma, LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio, Inc., and Others.


Hypertension Emerging Drugs Covered in the report include:

Firibastat: Quantum Genomics

Baxdrostat (CIN-107): CinCor Pharma

MLS-101: Mineralys Therapeutics 

Zilebesiran (ALN-AGT): Alnylam Therapeutics 

IONIS-AGT-LRx: Ionis Pharmaceuticals

Further product details are provided in the report. Download the sample pages to get more information:  https://www.delveinsight.com/sample-request/hypertension-pipeline-insight


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Hypertension Current Treatment Patterns

4. Hypertension – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Hypertension Late Stage Products (Phase-III)

7. Hypertension Mid-Stage Products (Phase-II)

8. Hypertension Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hypertension Discontinued Products

13. Hypertension Product Profiles

14. Key Companies in the Hypertension Market

15. Key Products in the Hypertension Therapeutics Segment

16. Dormant and Discontinued Products

17. Hypertension Unmet Needs

18. Hypertension Future Perspectives

19. Hypertension Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/hypertension-pipeline-insight


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Orthostatic Hypotension Market
“Orthostatic Hypotension Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Orthostatic Hypotension Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/